BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Lupin Opens Dedicated Oncology Manufacturing Block At Vizag Facility

Synopsis:


Lupin’s subsidiary Lupin Manufacturing Solutions has commissioned a 4,270 m² oncology block in Vizag with high-containment systems, 20 reactors and integrated labs to support oncology API development across research and commercial stages.


Source:
Lupin Press Release (NSE Exchange Fillings) | Published on Nov 12, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

As quoted in the press release of Lupin (NSE Exchange Filings), Lupin Manufacturing Solutions (LMS), a fully owned subsidiary of Lupin Ltd., has completed a sterilized high-containment oncology block within its facility in Vizag. This may be of interest to you if you track pharmaceutical manufacturing levels, oncology APIs, or the expansion of CDMO competencies. The oncology block enhances global oncology drug development capabilities for India at a time when demand for highly potent APIs is increasing.

LUPIN LIMITED

Trade

2044.410.50 (0.51 %)

Updated - 13 November 2025
2052.70day high
DAY HIGH
2033.50day low
DAY LOW
1490995
VOLUME (BSE)

Key Takeaways

  • 4,270 m² oncology block commissioned

  • 20 reactors ranging from 250 L to 2,000 L

  • Containment level maintained at ≤0.05 µg/m³

  • Batch range from 1 kg to 35 kg

  • Integrated labs for development and quality control

Also read: Mahindra & Mahindra and Manulife Sign 50:50 Life Insurance Deal

New Oncology Block: What To Know

The oncology block covers 4,270 square metres and features sophisticated containment systems to maintain limits of exposure ≥0.05 µg/m³. As one can imagine, this is very important because oncology APIs have safety controls in place due to potency. 

There are 20 reactors available at the facility, ranging from 250 L to 2,000 L, to facilitate development at various stages. The environmental controls are maintained at ≤25 °C and ≤45% RH to allow for production consistency.

Integrated Labs For Development And Quality

The new unit comprises a dedicated Process Development Laboratory and Quality Control Laboratory. You will appreciate the facility, where both teams can now work within the same block. Collaborating within the same area creates a smooth path for transition from early-stage route scouting through to scale-up and ultimately to validation.

By reducing technical gaps that commonly delay oncology manufacturing, the new unit provides a foundation to support early-phase research, analytical development, process optimisation and commercial execution all co-located.

High-Containment Infrastructure

LMS has furnished the block with over 20 isolators, SCADA-linked operations, and a dedicated wastewater detoxification system. This represents your shift towards global-compliant manufacturing, where containment is a critical part of the regulatory requirements for oncology compounds.

This system enables scalable production by allowing clients to adjust their processes from gram-scale reactions to commercial-scale batches within the same facility layout.

Facility Specifications At A Glance

Parameter

Detail

Area

4,270 m²

Reactor Capacity

250 L to 2,000 L

Batch Scale Range

1 kg to 35 kg

Containment

≤0.05 µg/m³ exposure levels

Environmental Controls

≤25 °C, ≤45% RH

Labs Integrated

Process Development Laboratory + Quality Control laboratory

Infrastructure

>20 isolators, SCADA systems, effluent detoxification

Industry Context

The oncology API space is growing due to more research and development globally. With this block, LMS is enhancing its CDMO capabilities, providing clients with more choices from early development through commercial manufacturing.

This also aligns with industry-wide trends toward more integrated, high-containment ecosystems rather than fragmented ones.

Share Price Update

Lupin share price stands at ₹2,033.90 per share on the BSE as of 12 November 2025 at 15:30 PM IST, up 2.94% from the previous close.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text